medigraphic.com
Revista Latinoamericana de Microbiología

2006, Number 2

<< Back Next >>

Microbiología 2006; 48 (2)

Infection agents
Brucella
Legionary disease
Identification of TEM y ROB-1 enzymes in rootstocks of Haemophilus influenzae isolated from de vaccinated

López MA, López MA, Contreras RA, Sapian LLA, Sergio BSG, Lozano ZP, Martínez LY, Rocha GRC

Language: Spanish
References: 44
Page: 146-153
PDF size: 122.85 Kb.


Text Extraction

No abstract


REFERENCES

  1. Ariza, J., T. Pellicer, R. Pallarés, A. Foz, and F. Gudiol. 1990. Specific antibody profile in human Brucellosis. Clin. Infect. Dis. 14: 131-140.

  2. Baldi, P.C., S.E. Miguel, C.A. Fossati, and J.C.Wallach. 1996. Serological follow-up of human brucellosis by measuring IgG antibodies to lipopolysaccharide and cytoplasmic proteins of Brucella species. Clin. Infect. Dis. 22: 446-455.

  3. Contreras Rodríguez A., B. Ramírez Zavala, A. Contreras, G. Schurig, N. Sriranganathan and A. López-Merino. 2003. Purification and characterization of an immunogenic aminopeptidase of Brucella melitensis. Infect. Immun. 71: 5239-5245.

  4. Corbel, M. J. 1997. Brucellosis: an overview. Emerg. Infect. Dis. 3: 213-221.

  5. Capasso L. 2002. Bacteria in two-millenia-old cheese, and related epizoonoses in Roman population. J. Infect. Dis. 45:122-127.

  6. Estrada Aguilera A. Aspectos clínicos de la brucelosis humana, en. E. Luna y F. Suárez.(eds) III Foro Nacional de Brucelosis, Memorias, SAGAR, CONASAG, UNAM, OPS, México, 1998, pag. 47-51

  7. Gazapo, E., J.L. Subiza, N. Baquero, and J.C.Gil. 1989. Changes in IgM and IgG antibody concentrations in brucellosis over time: importance for diagnosis and follow up. J. Infect. Dis. 159: 219-225.

  8. Goldbaum, F.A., L. Morelli, J. Wallach, C.P. Rubi, and C.A. Fossati. 1991. Human brucellosis: Immunobloting analysis of three Brucella abortus antigenic fractions allows the detection of components of diagnostic importance. Medicina (Buenos Aires) 51: 227-232.

  9. Gur A, M.F. Geyi, et al. 2003. Complications of brucellosis in different age groups: a study of 283 cases in southeastern Anatolia of TurkeyYonsei. Med. J., 44: 33-44

  10. Hernández M. I. Importancia de la brucelosis en salud pública, En: E. Luna y F. Suárez (eds) III Foro Nacional de Brucelosis, SAGAR, CONASAG, UNAM, OPS México, 1998, pag. 17-22.

  11. López-Merino A. Brucellosis in Latin America. Young EJ, Corbel MH, (eds). Brucellosis: clinical and laboratory aspects. Boca Ratón. CRC Press Inc., 1989, pag. 151-161

  12. Luna Martínez E. & C. Mejía Terán. 2002. Brucellosis in Mexico: current status and trends, Vet. Microbiol. 90: 19-30.

  13. Madkour M.M. Pregnancy and brucellosis, en, Madkour M.M. (ed) Brucellosis. Butterwoths Press, 1989, pag. 197-204.

  14. Norma Oficial Mexicana. NOM-022-SSA2-1994. Para la prevención y control de la brucelosis en el hombre, en el primer nivel de atención. Publicada en el Diario Oficial de la Federación el día 30 de noviembre de 1995.

  15. Sanakkayala, N., A. Sokolovska, J. Gulani, H. HogenEsch, N. Sriranganathan, S. Boyle, G. Schurig and R. Vemulapalli. 2005. Induction of antigen-specific Th1-type immunresponses by gamma-irradiated recombinant Brucella abortus Clin Diagn Lab Immunol 12: 1429-1436.

  16. Atlas, Ronald M. 1999. Legionella: from environmental habitats to disease pathology, detection and control. Environ Microbiol: 1, 283-293.

  17. Cano Portero, R. & C.A. Joseph. 2001. Community outbreak of legionnaires’ disease in Murcia, Spain Eurosurveillance Weekly. 5:010712.

  18. Fraser, D.W., T.R, Tsai, W., Orenstein, & cols. 1977. Legionnaires disease: description of an epidemic of pneumonia. N Engl J Med 297: 1189-1197.

  19. Glick, T.H., M.B., Gregg, B. G., Mallison, W.W. Jr., Rhodes, & I. Kassanoff. 1978. Pontiac fever: an epidemic of unknown etiology in a health department. I. Clinical and epidemiologic aspects. Am J Epidemiol 107: 149-160.

  20. http://www.cdc.gov/ncidod/dbmd/diseaseinfo/legionellosis_ t.html

  21. http://www.ewgli.org/data/data_tables/year_onset_country_ travel.asp

  22. Marston, B.J., H.B., Lipman, & R.F. Breiman. 1994. Surveillance for Legionnaires´ disease: risk factors for morbidity and mortality. Arch Intern Med 154: 2417-2422.

  23. Marín, V. I. & L. D. Montes, 1991. Neumonía por Legionella pneumophilla. Informe de un caso. Inv Med Int 17:205-209.

  24. Mc Dade, J.E., Shepard, C.C., Fraser, D.W., Tsai, T.R., Redus, M.A.& W.R., Dowdle. 1977. Legionnaires’ disease: isolation of a bacterium and demonstration of its role in other respiratory disease. N Engl J Med 297: 1197-1203.

  25. Sabria, M., Pedro-Botet, M. L., Gomez, J., Roig, J., Vilaseca, B., Sopena, N., Banos, V., for the Legionnaires Disease Therapy Group. 2005. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest 128: 1401-1405.

  26. Tison, D.L. & R.J. Seidler, 1983. Legionella: incidence and density in potable drinking water. Appl Environ Microbiol 45: 337-339.

  27. Torrijos, J.H., A., Lisker-Halpert, C.N., Pérez Redondo, K.K., Fujikami, S.V. Figueroa, & L., Castillo. 1995. La neumonía por Legionella pneumophilla. Informe del segundo caso en México. Gac Méd Mex 131: 587-590.

  28. Tsakris, A. S. Alexiou-Daniel, E. Souliou and A. Antoniadis .1999. In-vitro activity of antibiotics against Legionella pneumophila isolates from water systems J Antimicrob Chemother 44, 693-695.

  29. Villari, P., Mott, E., Farullo, C., Torre I. 1998. Comparison of conventional culture and PCR methods for the detection of Legionella pneumophila in water. Lett Appl Microbiol: 27: 106–110.

  30. Waterer GW, Baselski VS, Wunderink RG. 2001. Legionella and community-acquired pneumonia: a review of current diagnostic tests from a clinician’s viewpoint. Am J Med; 110: 41-48.

  31. Yu, V.L., J.F., Plouffe, M.C., Pastoris, J.E., Stout, M., Schousboe, A., Widmer, J., Summersgill, T., File, C.M., Heath, D.L., Paterson, & A. Cheresky. 2002. Distribution of Legionella species and serogroups isolated by culture in patients with sporadic community-acquired legionelosis: an international collaborative survey. J Infect Dis 186:127.

  32. Booy R & J. S. Kroll. 1997. Is Haemophilus influenzae finished? J. Antimicrob. Chemother. 40:149-153.

  33. Dabernat H., C. Delmas, M. Seguy, R. Pelissier, G. Faucon, S. Bennamani & C. Pasquier. 2002. Diversity of ß-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae. Antimicrob. Agents Chemother. 46(7):2208-2218.

  34. Jorgensen J. H. 1992. Update on mechanisms and prevalence of antimicrobial resistance in Haemophilus influenzae. Clin. Infect. Dis. 14:1119-1123.

  35. Karlowsky J. A., G Verma, G. G. Zhanel & D. J. Hoban. 2000 Presence of ROB-1 ß-lactamase correlates with cefaclor resistance among recent isolates of Haemophilus influenzae. J. Antimicrob. Chemother. 48: 871-875

  36. Casagrande, S.T., E.J. Vicente, I.M. Landgraf & A. M. M. Kobata. 2000. Antimicrobial resistance patterns of Haemophilus influenzae isolated from patients with meningitis in Sao Paulo, Brazil. Brazilian J. Med. Biol. Res. 33: 295-300.

  37. Scriver S.R., S.L. Walmsley, C. L. Kau, D. J. Hoban, J. Brunton, A. McGeer, T.C. Moore, E. Witwicki, Canadian Haemophilus study group & D. E. Low. 1994. Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their ß-lactamases. Antimicrob. Agents Chemother. 38:1678-1680.

  38. Molina J. M:, J. Córdoba, A. Monsoliu, U. Diosdado & M. Gobernado. 2003. Haemophilus influenzae and betalactam resistance: Description of blaTEM gene deletion. Rev. Esp. Quimioterap. 16(2):195-203.

  39. Sosa Iglesias E. G., S. Giono Cerezo, & A. Escobar Gutierrez. 1992. Manual de procedimientos para el aislamiento e identificación de Haemophilus. Publicación técnica del INDRE #19.SSA, México D. F.

  40. National Committee for Clinical Laboratory Standards. 1990. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A2. National Committee for Clinical Laboratory Standards, Villanova, Pa.

  41. National Committee for Clinical Laboratory Standards. 1992. Performance standards for antimicrobial susceptibility testing: 4th information supplement. NCCLS document M100-54. National Committee for Clinical Laboratory Standards, Villanova, Pa.

  42. Villaseñor Sierra A., E Herrera-Basto, P. Vázquez-Salazar, JA Arroyo Moreno & JI Santos Preciado. 1993. Prevalencia del estado de portador de Haemophilus influenzae en niños de Ciudad Nezahualcóyotl, Estado de México, México. Salud Púb. Mex. 38:87-93.

  43. Rocha Gracia R. C. y Sosa Iglesias E. G.1997. Portadores de Haemophilus influenzae en guarderías de las ciudades de Puebla y Minatitlán. Rev. Enf. Inf. Ped. Méx. 10(39): 80-86

  44. Sepúlveda M.E., L.V. Jiménez Rojas, M.L.E Espinosa. Prevalencia de serotipos en Haemophilus influenzae invasivos en el Hospital Infantil de México Federico Gómez, durante el período de 1997 a 2000. 2002. Boletín Médico del Hospital Infantil. 59(9):611-612.




2020     |     www.medigraphic.com